Vav-1 regulates NK T cell development and NK cell cytotoxicity

European Journal of Immunology

Volumn 31, Issue 8, 2001, Pages 2403-2410

  Chan, Gordon ^a,c   Hanke, Thomas ^a,c   Fischer, Klaus Dieter ^a,b,c  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Abteilung Physiologische Chemie   (Germany)

Author keywords

Cytotoxicity; NK cell; NK T cell; Vav 1

Indexed keywords

CD3 ANTIGEN; CELL RECEPTOR; FC RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 2; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; VAV PROTEIN;

ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL LINE; CELL MATURATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; MOUSE; MUTANT; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE;

ANIMALS; ANTIBODIES; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; ENZYME ACTIVATION; GENE DELETION; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-VAV; RECEPTORS, IGG;

EID: 0034856884     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200108)31:8<2403::AID-IMMU2403>3.0.CO;2-O     Document Type: Article

References (28)

1. Regulatory and signaling properties of the Vav family
2. Vav regulates peptide-specific apoptosis in thymocytes
3. + thymocytes
4. A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes
5. Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor
6. Defects in actin-cap formation in Vav-deficient mice implicate an actin requirement for lymphocyte signal transduction
7. Vav links antigen-receptor signaling to the actin cytoskeleton
8. Natural killer cells in antiviral defense: Function and regulation by innate cytokines
9. The Vav-Rac1 pathway in cytotoxic lymphocytes regulates the generation of cell-mediated killing
10. Specific subdomains of Vav differentially affect T cell and NK cell activation
11. Role for the Rac1 exchange factor Vav in the signaling pathways leading to NK cell cytotoxicity
12. RAC1/P38 MAPK signaling pathway controls beta1 integrin-induced interleukin-8 production in human natural killer cells
13. NKT cells: Facts, functions and fallacies
14. Identification of a common T/natural killer cell progenitor in human fetal thymus
15. CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3
16. + T cells are a potential source of IL-4 during primary immune response
17. Impaired NK1+ T cell development and early IL-4 production in CD1-deficient mice
18. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4
19. CD16 cross-linking induces both secretory and extracellular signal-regulated kinase (ERK)-dependent cytosolic phospholipase A2 (PLA2) activity in human natural killer cells: Involvement of ERK, but not PLA2, exocytosis
20. Differential role of p38 and c-Jun N-terminal kinase 1 mitogen-activated protein kinases in NK cell cytotoxicity
21. The Src family tyrosine kinase Fyn regulates natural killer T cell development
22. Inaugural article: T-cell receptor antagonists induce vav phosphorylation by selective activation of fyn kinase
23. Lck regulates Vav activation of members of the Rho family of GTPases
24. The oncogene product Vav is a crucial regulator of primary cytotoxic T cell responses but has no apparent role in CD28-mediated co-stimulation
25. The Rho family guanine nucleotide exchange factor Vav-2 regulates the development of cell-mediated cytotoxicity
26. Compensation between Vav-1 and Vav-2 in B cell development and antigen receptor signaling
27. Turning on natural killer cells
28. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors